Article Details

Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno ...

Retrieved on: 2018-01-07 20:56:15

Tags for this article:

Click the tags to see associated articles and topics

Teneobio Announces a Strategic Alliance with TESARO to Develop the Next Generation of Immuno .... View article details on hiswai:

Excerpt

<div>... optimal efficacy and reduced toxicity. Teneobio plans to file its first IND on its lead program, TNB-383B (anti-BCMAxCD3) for the treatment of multiple myeloma in Q4 of 2018. The company has received funding from institutional investors, including <b>Lightspeed Venture Partners</b> and Sutter Hill Ventures.</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up